558 related articles for article (PubMed ID: 32125907)
1. Silence superoxide dismutase 1 (SOD1): a promising therapeutic target for amyotrophic lateral sclerosis (ALS).
Abati E; Bresolin N; Comi G; Corti S
Expert Opin Ther Targets; 2020 Apr; 24(4):295-310. PubMed ID: 32125907
[No Abstract] [Full Text] [Related]
2. Silencing strategies for therapy of SOD1-mediated ALS.
van Zundert B; Brown RH
Neurosci Lett; 2017 Jan; 636():32-39. PubMed ID: 27507699
[TBL] [Abstract][Full Text] [Related]
3. SOD1 in neurotoxicity and its controversial roles in SOD1 mutation-negative ALS.
Hayashi Y; Homma K; Ichijo H
Adv Biol Regul; 2016 Jan; 60():95-104. PubMed ID: 26563614
[TBL] [Abstract][Full Text] [Related]
4. Mutant SOD1 mediated pathogenesis of Amyotrophic Lateral Sclerosis.
Kaur SJ; McKeown SR; Rashid S
Gene; 2016 Feb; 577(2):109-18. PubMed ID: 26657039
[TBL] [Abstract][Full Text] [Related]
5. In vivo genome editing improves motor function and extends survival in a mouse model of ALS.
Gaj T; Ojala DS; Ekman FK; Byrne LC; Limsirichai P; Schaffer DV
Sci Adv; 2017 Dec; 3(12):eaar3952. PubMed ID: 29279867
[TBL] [Abstract][Full Text] [Related]
6. Does wild-type Cu/Zn-superoxide dismutase have pathogenic roles in amyotrophic lateral sclerosis?
Furukawa Y; Tokuda E
Transl Neurodegener; 2020 Aug; 9(1):33. PubMed ID: 32811540
[TBL] [Abstract][Full Text] [Related]
7. CRISPR/Cas9-Mediated Gene Correction to Understand ALS.
Yun Y; Ha Y
Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32471232
[TBL] [Abstract][Full Text] [Related]
8. Approaches to Gene Modulation Therapy for ALS.
Meijboom KE; Brown RH
Neurotherapeutics; 2022 Jul; 19(4):1159-1179. PubMed ID: 36068427
[TBL] [Abstract][Full Text] [Related]
9. Gene Therapy in Amyotrophic Lateral Sclerosis.
Fang T; Je G; Pacut P; Keyhanian K; Gao J; Ghasemi M
Cells; 2022 Jun; 11(13):. PubMed ID: 35805149
[TBL] [Abstract][Full Text] [Related]
10. Perspective on SOD1 mediated toxicity in Amyotrophic Lateral Sclerosis.
Sangwan S; Eisenberg DS
Postepy Biochem; 2016; 62(3):362-369. PubMed ID: 28132491
[TBL] [Abstract][Full Text] [Related]
11. ERp57 is protective against mutant SOD1-induced cellular pathology in amyotrophic lateral sclerosis.
Parakh S; Jagaraj CJ; Vidal M; Ragagnin AMG; Perri ER; Konopka A; Toth RP; Galper J; Blair IP; Thomas CJ; Walker AK; Yang S; Spencer DM; Atkin JD
Hum Mol Genet; 2018 Apr; 27(8):1311-1331. PubMed ID: 29409023
[TBL] [Abstract][Full Text] [Related]
12. Seeding activity of human superoxide dismutase 1 aggregates in familial and sporadic amyotrophic lateral sclerosis postmortem neural tissues by real-time quaking-induced conversion.
Mielke JK; Klingeborn M; Schultz EP; Markham EL; Reese ED; Alam P; Mackenzie IR; Ly CV; Caughey B; Cashman NR; Leavens MJ
Acta Neuropathol; 2024 Jun; 147(1):100. PubMed ID: 38884646
[TBL] [Abstract][Full Text] [Related]
13. The molecular tweezer CLR01 inhibits aberrant superoxide dismutase 1 (SOD1) self-assembly
Malik R; Meng H; Wongkongkathep P; Corrales CI; Sepanj N; Atlasi RS; Klärner FG; Schrader T; Spencer MJ; Loo JA; Wiedau M; Bitan G
J Biol Chem; 2019 Mar; 294(10):3501-3513. PubMed ID: 30602569
[TBL] [Abstract][Full Text] [Related]
14. Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations.
Mackenzie IR; Bigio EH; Ince PG; Geser F; Neumann M; Cairns NJ; Kwong LK; Forman MS; Ravits J; Stewart H; Eisen A; McClusky L; Kretzschmar HA; Monoranu CM; Highley JR; Kirby J; Siddique T; Shaw PJ; Lee VM; Trojanowski JQ
Ann Neurol; 2007 May; 61(5):427-34. PubMed ID: 17469116
[TBL] [Abstract][Full Text] [Related]
15. Delayed disease onset and extended survival in the SOD1G93A rat model of amyotrophic lateral sclerosis after suppression of mutant SOD1 in the motor cortex.
Thomsen GM; Gowing G; Latter J; Chen M; Vit JP; Staggenborg K; Avalos P; Alkaslasi M; Ferraiuolo L; Likhite S; Kaspar BK; Svendsen CN
J Neurosci; 2014 Nov; 34(47):15587-600. PubMed ID: 25411487
[TBL] [Abstract][Full Text] [Related]
16. The deletion of mutant SOD1 via CRISPR/Cas9/sgRNA prolongs survival in an amyotrophic lateral sclerosis mouse model.
Duan W; Guo M; Yi L; Liu Y; Li Z; Ma Y; Zhang G; Liu Y; Bu H; Song X; Li C
Gene Ther; 2020 Apr; 27(3-4):157-169. PubMed ID: 31819203
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic rAAVrh10 Mediated SOD1 Silencing in Adult SOD1(G93A) Mice and Nonhuman Primates.
Borel F; Gernoux G; Cardozo B; Metterville JP; Toro Cabrera GC; Song L; Su Q; Gao GP; Elmallah MK; Brown RH; Mueller C
Hum Gene Ther; 2016 Jan; 27(1):19-31. PubMed ID: 26710998
[TBL] [Abstract][Full Text] [Related]
18. Novel behavioural characteristics of the superoxide dismutase 1 G93A (SOD1
Kreilaus F; Guerra S; Masanetz R; Menne V; Yerbury J; Karl T
Genes Brain Behav; 2020 Feb; 19(2):e12604. PubMed ID: 31412164
[TBL] [Abstract][Full Text] [Related]
19. Single copy/knock-in models of ALS SOD1 in C. elegans suggest loss and gain of function have different contributions to cholinergic and glutamatergic neurodegeneration.
Baskoylu SN; Yersak J; O'Hern P; Grosser S; Simon J; Kim S; Schuch K; Dimitriadi M; Yanagi KS; Lins J; Hart AC
PLoS Genet; 2018 Oct; 14(10):e1007682. PubMed ID: 30296255
[TBL] [Abstract][Full Text] [Related]
20. Wild-type Cu/Zn-superoxide dismutase is misfolded in cerebrospinal fluid of sporadic amyotrophic lateral sclerosis.
Tokuda E; Takei YI; Ohara S; Fujiwara N; Hozumi I; Furukawa Y
Mol Neurodegener; 2019 Nov; 14(1):42. PubMed ID: 31744522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
